Loading...

ニュース

VISEN Pharmaceutical's TransCon C-type natriuretic peptide Phase II clinical trial application approved in China

2021-02-08


January 7, VISEN Pharmaceuticals announced that it had submitted TransCon CNP (TransCon C-type natriuretic peptide) for injection to the National Medical Products Administration (NMPA) for the treatment of achondroplasia (ACH) patients. Phase II new drug clinical trial application has been approved. The ACcomplisH China clinical trial is about to be launched in China, achieving global synchronization with ACcomplisH (a TransCon C-type natriuretic peptide phase II global clinical trial being carried out by Ascendis Pharma).


TransCon CNP inhibits the over-activated fibroblast growth factor receptor 3 (FGFR3) signaling pathway by continuously providing active CNP. Slowly released once a week to help children with ACH rebuild the balance of bone growth, while improving and preventing the complications of ACH. TransCon CNP has obtained orphan drug designation from the US Food and Drug Administration and the European Commission.


当社は、このウェブサイトの利用状況をより良く理解し、今後のウェブサイト訪問時の体験を向上させるために、クッキーを使用したいと考えています。この設定は、ブラウザの設定で変更できます。クッキーの使用に関する詳細については、当社の プライバシー ポリシー を参照してください。